Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 21, 2024
Reporting Period: Event-based report regarding the closing of a private placement offering.
Key Financial Metrics
This filing reports on a capital raise rather than operational financial performance. Key metrics include:
- Total Gross Proceeds: $790,000 (from the full Offering).
- Second Closing Proceeds: $220,000 received on October 21, 2024.
- Second Closing Investment Amount: $231,579 in Notes and Warrants.
- First Closing Proceeds: $600,000 (closed October 14, 2024).
- Instrument Details: 5% original issue discount senior secured convertible notes and warrants.
- Warrant Exercise Price: $1.49 per share (125% of the closing price prior to closing).
- Warrant Quantity (Second Closing): 88,544 warrants issued.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt levels outside of this specific transaction.
Material Changes
The primary material change is the completion of a previously announced up to $1.3 million offering. The Offering concluded with total gross proceeds of $790,000, which is below the maximum potential raise. The Second Closing involved two accredited investors purchasing the remaining tranche of the offering.
Guidance, Outlook, and Risks
- Management Commentary: The filing confirms the successful closure of the Offering, noting that the Company's Chief Executive Officer, Dr. Anatoly Dritschilo, invested $237,500 in the First Closing.
- Regulatory Status: The Notes and Warrants were sold pursuant to private placement exemptions (Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D) and are not registered under the Securities Act.
- Unusual Items: The offering includes senior secured convertible notes with a 5% original issue discount.
- Outlook: No specific forward-looking guidance regarding product development or future revenue was included in this specific filing.
Investor Verification Checklist
- Verify the full terms of the Senior Secured Convertible Notes and Warrants in the Purchase Agreement (Exhibit 10.1) and Note/Warrant forms (Exhibits 10.2 and 10.3) referenced from the October 17, 2024 filing.
- Confirm the dilution impact of the 88,544 warrants issued in the Second Closing plus any warrants issued in the First Closing.
- Review the Company's cash position post-closing to assess runway, as this filing does not provide a balance sheet.
- Check for any subsequent filings regarding the use of the $790,000 in proceeds.